Binds Specifically-identified Oligosaccharide Structure Patents (Class 424/137.1)
-
Patent number: 7597893Abstract: The present application relates to a human monoclonal antibody specific for the serotype IATS 06 of P. aeruginosa, a hybridoma producing it, nucleic acids encoding it, and host cells transfected therewith. Further, the present invention relates to methods for producing said monoclonal antibody. In addition, the present invention relates to pharmaceutical compositions comprising at least one antibody or at least one nucleic acid encoding said antibody.Type: GrantFiled: November 10, 2005Date of Patent: October 6, 2009Assignee: Kenta Biotech AGInventors: Alois B. Lang, Michael P. Horn, Martin A. Imboden
-
Publication number: 20090246200Abstract: The present invention presents the isolation, characterization and synthesis of oligosaccharides of Bacillus anthracis. Also presented are antibodies that bind to such saccharide moieties and various methods of use for such saccharide moieties and antibodies.Type: ApplicationFiled: December 24, 2008Publication date: October 1, 2009Inventors: Russell W. Carlson, Geert-Jan Boons, Therese Buskas, Biswa Choudhury, Elmar Kannenberg, Christine Leoff, Alok Mehta, Elke Saile, Jana Rauvolfova, Conrad Quinn, Patricia Wilkins, Mahalakshmi Vasan, Margreet A. Wolfert
-
Publication number: 20090220509Abstract: The present invention relates to agents capable of binding sialic acid-binding immunoglobulin-like lectin-9 (Siglec-9) and their use in the treatment of cell proliferation and differentiation disorders. Furthermore, the present invention provides associated pharmaceutical formulations and methods.Type: ApplicationFiled: October 27, 2006Publication date: September 3, 2009Inventors: Paul Richard Crocker, Bjoern Biedermann
-
Publication number: 20090191203Abstract: The present invention relates to BCMA polypeptide variants and their uses, particularly for therapeutic or prophylactic treatment in human subjects. The invention also relates to nucleic acids encoding said polypeptides, vectors comprising such nucleic acids and recombinant cells containing the same. The invention further discloses methods of producing such polypeptides, as well as methods and tools for detecting or dosing these polypeptides in any sample.Type: ApplicationFiled: December 22, 2005Publication date: July 30, 2009Applicant: Laboratoires Serono S.A.Inventors: Benedicte Belloir, Anne-Francoise Cledat, Gwenael Primas
-
Publication number: 20090191204Abstract: Immunoglobulin chains or antibodies having light or heavy chain complementarity determining regions of antibodies that bind to P-Selectin Glycoprotein Ligand-1. Also disclosed are methods of inducing death of an activated T-cell and of modulating a T cell-mediated immune response in a subject.Type: ApplicationFiled: March 6, 2009Publication date: July 30, 2009Applicant: AbGenomics Cooperatief U.A.Inventors: Rong-Hwa Lin, Chung Nan Chang, Pei-Jiun Chen, Chiu-Chen Huang
-
Patent number: 7541033Abstract: The present invention encompasses isolated antibodies, or antigen-binding portions thereof, that specifically bind mature human IL-1 Beta. These antibodies, or antigen-binding portions thereof, generally exhibit high binding affinities (low kooff values), reduced deamidation compared to the native antibody, and can be used to treat various diseases such as rheumatoid arthritis, osteoarthritis, or neuroinflammation.Type: GrantFiled: January 21, 2004Date of Patent: June 2, 2009Assignee: Applied Molecular Evolution, Inc.Inventors: Craig Duane Dickinson, Alain Philippe Vasserot, Jeffry Dean Watkins, Jirong Lu
-
Publication number: 20090118141Abstract: The present invention provides methods for identifying oligosaccharides specific to an inflammatory or infectious disease, methods for diagnosing an inflammatory or infectious disease by detecting the presence or absence of such oligosaccharides, and methods for treating an inflammatory or infectious disease by administering antibodies directed to such oligosaccharides. The present invention also provides methods for diagnosing ocular rosacea by determining the presence or absence of specific oligosaccharide markers. In addition, the present invention provides markers for ocular rosacea comprising 0-linked oligosaccharides as well as kits for diagnosing or treating ocular rosacea.Type: ApplicationFiled: May 3, 2006Publication date: May 7, 2009Applicant: The Regents of the University of CaliforniaInventors: Carlito B. Lebrilla, Hyunjoo An, Lenio S. Alvarenga, Mark D. Mannis
-
Patent number: 7521432Abstract: Novel compositions and methods are provided for identifying agents which affect chromosomal stability and aging.Type: GrantFiled: April 25, 2007Date of Patent: April 21, 2009Assignee: Wisconsin Alumni Research FoundationInventors: John M. Denu, Kirk G. Tanner
-
Publication number: 20090017029Abstract: The present invention relates to identification of a human gene, Complement Factor H (CFH), associated with the occurrence for developing age related macular degeneration (AMD), which is useful for identifying or aiding in identifying individuals at risk for developing AMD, as well as for diagnosing or aiding in the diagnosis or AMD.Type: ApplicationFiled: November 18, 2005Publication date: January 15, 2009Applicants: YALE UNIVERSITY, THE ROCKEFELLER UNIVERSITYInventors: Josephine Hoh, Robert J. Klein
-
Patent number: 7470428Abstract: The present invention provides compositions and methods useful for promoting or reducing T-cell trafficking to a target tissue. Also provided are compositions and methods useful for promoting or inhibiting antigen-presenting cell (APC) activation. The invention is related to discovery of functional characteristics of TIM-3, a molecule that is preferentially expressed on the surface of Th1 cells. The methods are useful for treating disorders including cancer, infectious disease, allergy, asthma, and autoimmune disease.Type: GrantFiled: January 30, 2003Date of Patent: December 30, 2008Assignees: The Brigham and Women's Hospital, Inc., Dana-Farber Cancer InstituteInventors: Vijay Kuchroo, Laurent Monney, Jason L. Gaglia, Edward A. Greenfield, Gordon J. Freeman, Hanspeter Waldner
-
Publication number: 20080299123Abstract: The present invention relates to the use of L1 interfering molecules, especially anti-L1 antibodies, in tumor treatment. Especially, the present invention relates to the use of said L1 interfering molecules in sensitizing tumor cells for the treatment with chemotherapeutic drugs of with radiotherapy and to the combined administration of L1 interfering molecules with chemotherapeutic drugs or with radiotherapy.Type: ApplicationFiled: October 5, 2007Publication date: December 4, 2008Inventors: Peter Altevogt, Alexander Stoeck, Daniela Gast, Susanne Sebens Muerkoster, Heiner Schafer
-
Publication number: 20080299122Abstract: The invention provides methods for modulating the immune system using anti-CD83 antibodies that can influence CD83 function.Type: ApplicationFiled: May 23, 2007Publication date: December 4, 2008Applicant: UCB SAInventors: Leon Fernando Garcia-Martinez, Yuching Chen, Dawn Andrews
-
Publication number: 20080241143Abstract: This invention relates to the inhibition of intercellular adhesion mediated by L-selectin by administering a newly identified L-selectin ligand, CD34. More particularly, the invention concerns a method for inhibiting leukocyte adhesion to endothelial cells by administering an effective amount of an isolated, purified CD34 polypeptide or an antibody capable of binding native CD34.Type: ApplicationFiled: September 26, 2007Publication date: October 2, 2008Inventors: Laurence A. Lasky, Susanne Baumhueter, Steven D. Rosen, Mark S. Singer
-
Publication number: 20080213268Abstract: Novel anti-NRP1 antibodies and variants thereof having unique structural and functional characteristics are disclosed. Also provided are uses of the antibodies in research, diagnostic and therapeutic applications.Type: ApplicationFiled: April 22, 2008Publication date: September 4, 2008Inventors: Ryan J. Watts, Yan Wu
-
Patent number: 7416725Abstract: The present invention provides compositions that enhance or inhibit the interactions of galectin-8 and galectin-8-like proteins with other extracellular matrix proteins or cell surface receptors, and methods for the use thereof as physiological modulators of cell adhesion and in treatment of tumors, both in vivo or ex vivo. It further provides compositions and methods for modulating the expression of galectin-8, and galectin-8-like proteins, particularly to novel antisense oligonucleotides.Type: GrantFiled: December 19, 2006Date of Patent: August 26, 2008Assignee: Yeda Research and Development Co. Ltd.Inventors: Yehiel Zick, Yifat Levy, Rinat Arbel-Goren, Denise Ronen, Yaron R. Hadari
-
Publication number: 20080193452Abstract: The present invention is directed to new therapeutic compounds isolated from spider venom and methods of using these new compounds. The compounds are sulfated nucleoside derivatives including ribonucleoside mono- and disulfates derived from guanine, adenosine, and cytidine. Some of these compounds are glycosylated or fucosylated bearing one or more sugar residues.Type: ApplicationFiled: July 21, 2005Publication date: August 14, 2008Applicant: Cornell Research Foundation, Inc.Inventors: Jerrold Meinwald, Andrew Edmund Taggi, Frank Clemens Schroeder
-
Patent number: 7399470Abstract: A sandwich immunoassay kit for detecting ciguatoxins based on a combination of two anti-ciguatoxin CTX3C monoclonal antibodies produced by hybridomas, 3D11 (deposited at IPOD, AIST under accession number FMRM PB-8293) and 10C9 (FMRM PB-8292). In particular, one of the antibodies is labeled and each of them binds specifically to a different site of ciguatoxin CTX3C.Type: GrantFiled: March 10, 2003Date of Patent: July 15, 2008Assignee: Japan Science and Technology AgencyInventors: Masahiro Hirama, Hiroki Oguri, Ikuo Fujii, Takeshi Tsuburaya
-
Patent number: 7364733Abstract: The invention provides purified ACT-4 receptor polypeptides, antibodies against these polypeptides and nucleic acids encoding ACT-4 receptor polypeptides. Also provided are methods of diagnosis and treatment using the same. ACT-4 receptors are preferentially expressed on the surface of activated CD4+ T-cells. ACT-4 receptors are usually expressed at low levels on the surface of activated CD8+ cells, and are usually substantially absent on resting T-cells, and on monocytes and B-cells (resting or activated). An exemplary ACT-4 receptor, termed ACT-4-h-1, has a signal sequence, an extracellular domain comprising three disulfide-bonded intrachain loops, a transmembrane domain, and an intracellular domain.Type: GrantFiled: March 22, 2004Date of Patent: April 29, 2008Assignees: The Board of Trustees of the Leland Stanford Junior University, Becton Dickinson and CompanyInventors: Wayne Godfrey, David Buck, Edgar G. Engleman
-
Patent number: 7291606Abstract: Novel compositions and methods are provided for identifying agents which affect chromosomal stability and aging.Type: GrantFiled: November 13, 2001Date of Patent: November 6, 2007Assignee: Wisconson Alumni Research FoundationInventors: John M. Denu, Kirk G. Tanner
-
Patent number: 7259247Abstract: A polypeptide (8F4 molecule) with a T-cell costimulating biological activity is disclosed, as well as monoclonal antibodies against said 8F4 molecule and hybridoma cells which produce the monoclonal antibodies, the use as medicaments of substances which inhibit the biological activity of the disclosed 8F4 polypeptide, in particular monoclonal antibodies, natural or synthetic ligands, agonists or antagonists, in particular for preventing or treating diseases which involve the immune system, the use of said 8F4 molecule or cells containing said 8F4 molecule as medicaments, in particular for preventing or treating diseases which involve the immune system, and the use of substances which specifically recognize the disclosed polypeptide, in particular monoclonal antibodies, natural or synthetic ligands, agonists or antagonists, for diagnosing diseases which involve the immune system.Type: GrantFiled: September 23, 1998Date of Patent: August 21, 2007Assignee: Bundersrespublik Deutschaland Letztvertreten Durch Den Direktor Des Robert-Koch-InstitutesInventor: Richard Kroczek
-
Patent number: 7253263Abstract: The present invention relates to a human CDR-grafted antibody against ganlioside GD3 (hereinafter referred to “GD3”), derivatives of an anti-GD3 antibody and cytokine, and use for treatment and diagnosis of the antibody and the derivatives.Type: GrantFiled: September 29, 2000Date of Patent: August 7, 2007Assignee: Kyowa Hakko Kogyo Co., Ltd.Inventors: Nobuo Hanai, Kenya Shitara, Kazuyasu Nakamura, Rinpel Niwa
-
Patent number: 7244430Abstract: The invention provides human binding molecules specifically binding to West Nile virus and having West Nile virus neutralizing activity, nucleic acid molecules encoding the human binding molecules, compositions comprising the human binding molecules and methods of identifying or producing the human binding molecules. The human binding molecules can be used in the diagnosis, post-exposure prophylaxis and/or treatment of a condition resulting from West Nile virus.Type: GrantFiled: January 22, 2007Date of Patent: July 17, 2007Assignee: Crucell Holland B.V.Inventors: Mark Throsby, Cornelis Adriaan De Kruif
-
Patent number: 7241592Abstract: Antibodies to the CNA protein and to other regions from the collagen binding domain, including domain CNA19, are provided, and antibodies produced in this manner have been shown to be cross reactive to both Staphylococcus aureus and Staphylococcus epidermidis bacteria and which can thus be used in the prevention and treatment of infections caused by both of these types of bacteria. In addition, medical instruments can be treated using the antibodies of the invention in order to reduce or eliminate the possibility of their becoming infected or further spreading the infection. In particular, the proteins are advantageous because they are cross-reactive and may thus be administered to patients so as to reduce or prevent severe infection by staphylococcal bacteria of more than one species.Type: GrantFiled: March 19, 2001Date of Patent: July 10, 2007Assignees: Universita Degli Studi di Pavia, The Texas A&M University System, Inhibitex, Inc.Inventors: Magnus Hook, Yi Xu, Pietro Speziale, Livia Visal, Fabrizia Casolini, Joseph M. Patti, Pratiksha Patel, Paul Domanski
-
Patent number: 7235644Abstract: A vaccine, effective in inducing the production of antibodies with which to immunize a second subject passively against infection by Gram-negative bacteria and LPS-mediated pathology, comprises a non-covalent polyvalent complex formed between purified, detoxified LPS derived from E. coli and purified outer membrane protein derived from N. meningitidis. The same vaccine will also actively immunize a host subject against Gram-negative bacterial infections and LPS-mediated pathology. Meningococcal infections are included among those Gram-negative bacterial infections protected against by the vaccine.Type: GrantFiled: March 15, 2006Date of Patent: June 26, 2007Assignee: United States of America as represented by the Secretary of the ArmyInventors: Apurba Bhattacharjee, Alan Cross, Jerald Sadoff, Wendell Zollinger
-
Patent number: 7198787Abstract: A method for killing unwanted target cells in a cell population comprising nucleated cells harvested from peripheral blood, or CD-34+ or similar early progenitor cells selected from the above nucleated cells or from bone marrow aspirates, in which method the cell population is in vitro or in vivo exposed to two or more immunotoxins selectively killing the malignant cells, is described. Furthermore the invention relates to the mixture of immunotixins, the use of the mixture and a kit for performing the method.Type: GrantFiled: March 12, 1997Date of Patent: April 3, 2007Assignee: Oystein FodstadInventors: Oystein Fodstad, Gunnar Kvalbeim, Meng yu Wang, Olav Engebraten, Siri Juell
-
Patent number: 7189395Abstract: The present invention relates to complexes consisting of immunoglobulins and polysaccharides for oral and transmucosal use. The polysaccharides comprised in the complexes according to the invention form an envelope which protects and carries immunoglobulins allowing their systemic absorption through the gastric and mucosal district. Immunoglobulins have a different specificity depending on the required therapeutic effect. They are used in passive immunoprophylaxis for the prevention or therapy of infections caused by pathogenic agents such as virus, bacteria, parasites, or they are used in the modulation of endogenous bio-chemical balances, or in the detoxification from drugs of abuse, medicines, toxins.Type: GrantFiled: April 7, 2005Date of Patent: March 13, 2007Assignee: Grisotech S.A.Inventors: Rolando Wyss, Bernad Bizzini, Ivo Volpato
-
Patent number: 7175990Abstract: The present invention provides a method of predicting the probability of a successful pregnancy, either a naturally achieved pregnancy or a pregnancy resulting from an assisted reproductive technology, based on the level of L-selectin ligand expressed by uterine epithelial cells and/or the level of L-selectin expressed by an embryo in vitro. The invention further provides methods of inhibiting cell adhesion between a trophoblast and a uterine epithelial cell. Methods of inhibiting cell adhesion between a trophoblast and a uterine epithelial cell are useful to inhibit pregnancy. The invention further provides methods of assessing in vitro embryo quality. The invention further provides methods of predicting the probability of continued success of a pregnancy during the first 16 weeks of gestation.Type: GrantFiled: February 25, 2003Date of Patent: February 13, 2007Assignee: The Regents of the University of CaliforniaInventors: Susan J. Fisher, Olga Genbacev-Krtolica, Akraporn Prakobphol, Michael T. McMaster
-
Patent number: 7147850Abstract: The invention provides therapeutic compositions comprising binding agents that specifically bind to tumor-associated MUC-1 and reduce, reverse or prevent their effects in cancer. More particularly, the invention provides therapeutic compositions that comprise a binding agent that can specifically bind to an epitope that comprises both peptide and carbohydrate on such tumor-associated MUC-1. The invention further provides methods for the use of such therapeutic compositions in the treatment of cancer.Type: GrantFiled: November 26, 2001Date of Patent: December 12, 2006Assignee: AltaRex Medical Corp.Inventor: Ragupathy Madiyalakan
-
Patent number: 7105303Abstract: Two Hepatitis C Virus envelope proteins (E1 and E2) are expressed without sialylation. Recombinant expression of these proteins in lower eukaryotes, or in mammalian cells in which terminal glycosylation is blocked, results in recombinant proteins which are more similar to native HCV glycoproteins. When isolated by GNA lectin affinity, the E1 and E2 proteins aggregate into virus-like particles.Type: GrantFiled: August 13, 2001Date of Patent: September 12, 2006Assignee: Novartis Vaccines and Diagnostics, Inc.Inventors: Robert O. Ralston, Frank Marcus, Kent B. Thudium, Barbara A. Gervase, John A. Hall, Kim M. Berger, Qui-Lim Choo, Michael Houghton, George Kuo
-
Patent number: 7064191Abstract: The present invention relates to a process for purifying an antibody having a desired property, which comprises using a substance having an affinity to a carbohydrate binding to the antibody; a medicament comprising, as an active ingredient, the antibody purified by the process; and a method for diagnosing or preventing various diseases, which comprises using a substance having an affinity to a carbohydrate binding to an antibody.Type: GrantFiled: October 4, 2001Date of Patent: June 20, 2006Assignee: Kyowa Hakko Kogyo Co., Ltd.Inventors: Toyohide Shinkawa, Kazuhisa Uchida, Motoo Yamasaki, Emi Hosaka, Kenya Shitara
-
Patent number: 7060495Abstract: The invention relates to compounds which contain an antigen binding region which is bound to at least one enzyme which is able to metabolize a compound (prodrug) which has little or no cytotoxicity to a cytotoxic compound (drug), where the antigen binding region is composed of a single polypeptide chain. It is advantageous for covalently bonded carbohydrates to be present on the polypeptide chain.Type: GrantFiled: December 12, 1997Date of Patent: June 13, 2006Assignee: Behrinwerke AktienegesellschaftInventors: Mathias Gehrmann, Gerhard Seemann, Klaus Bosslet, Jörg Czech
-
Patent number: 7041634Abstract: This invention provides a method of inhibiting viable cells transplanted into a subject from being destroyed by the subject's immune system which comprises: a) containing the viable cells, or tissue comprising the viable cells, prior to transplantation within a device comprising a semipermeable membrane; and b) treating the subject with a substance which inhibits an immune-system costimulation event in an amount effective to inhibit the subject's immune system from responding to said contained cells or tissue. In one embodiment, the substance which inhibits an immune-system costimulation event is CTLA4.Type: GrantFiled: March 27, 1998Date of Patent: May 9, 2006Assignees: Emory University, Bristol Myers-Squibb CompanyInventors: Collin J. Weber, Mary K. Hagler, Peter S. Linsley, Judith A. Kapp, Susan A. Safley
-
Patent number: 7030225Abstract: A cell surface molecule that is expressed specifically in thymocytes, lymphocytes activated by ConA-stimulation, and peripheral blood lymphocytes. This molecule is involved in signal transmission of the secondary signal (costimulatory signal) essential for the activation of lymphocytes such as T cells and regulates functions of activated lymphocytes such as activated T cells. Disclosed are an antibody or a portion thereof, which binds to a polypeptide of the cell surface molecule, a polypeptide fragment thereof, or a fusion polypeptide comprising the fragment; a cell secreting the antibody or its portion; a pharmaceutical composition comprising the antibody; and methods of using the compositions for therapeutic, diagnostic and/or experimental purpose.Type: GrantFiled: August 26, 1999Date of Patent: April 18, 2006Assignee: Japan Tobacco, Inc.Inventors: Takuya Tamatani, Katsunari Tezuka
-
Patent number: 7025963Abstract: A vaccine, effective in inducing the production of antibodies with which to immunize a second subject passively against infection by Gram-negative bacteria and LPS-mediated pathology, comprises a non-covalent polyvalent complex formed between purified, detoxified LPS derived from E. coli and purified outer membrane protein derived from N. meningitidis. The same vaccine will also actively immunize a host subject against Gram-negative bacterial infections and LPS-mediated pathology. Meningococcal infections are included among those Gram-negative bacterial infections protected against by the vaccine.Type: GrantFiled: June 6, 1995Date of Patent: April 11, 2006Assignee: United States of America as represented by the Secretary of the ArmyInventors: Apurba Bhattacharjee, Alan Cross, Jerald Sadoff, Wendell Zollinger
-
Patent number: 6956119Abstract: Disclosed is a method of producing a polysaccharide-polypeptide conjugate by reacting a polysaccharide with a polypeptide which contains at least one free amino group, wherein a polysaccharide carrier comprising vicinal hydroxyl groups is oxidized under ring opening to create vicinal aldehyde groups and is reacted with one or more base-instable antigenic polypeptide(s) containing at least one free amino group, the polypeptide(s) being bound directly to the polysaccharide carrier via at least one azomethine bond.Type: GrantFiled: March 21, 2001Date of Patent: October 18, 2005Inventors: Hans Loibner, Helmut Eckert
-
Patent number: 6946130Abstract: Chimeric, humanized and other IL-5 mAbs, derived from high affinity neutralizing mAbs, pharmaceutical compositions containing same, methods of treatment and diagnostics are provided.Type: GrantFiled: November 4, 2003Date of Patent: September 20, 2005Assignees: SmithKline Beecham Corporation, SmithKline Beecham p.l.c.Inventors: Robert S. Ames, Edward Robert Appelbaum, Irwin M. Chaiken, Richard M. Cook, Mitchell Stuart Gross, Stephen Dudley Holmes, Lynette Jane McMillan, Timothy Wayne Theisen
-
Patent number: 6919080Abstract: A novel peptide obtained from Haemophilus paragallinarum has been found useful for preventing avian infectious coryza. This polypeptide induces production of hemagglutination-inhibition antibody and prevents infection and onset of avian infectious coryza. The invention further provides a gene coding for the polypeptide, a recombinant vector for expression of this gene, a host transformed with this vector, a process for preparing the polypeptide in a host, a vaccine for avian infectious coryza comprising the polypeptide as an active ingredient, a monoclonal antibody obtained using the polypeptide as an immunogen, and a diagnostic agent and a therapeutic agent for avian infectious coryza using the peptide and the antibody.Type: GrantFiled: July 11, 2002Date of Patent: July 19, 2005Assignee: Juridical Foundation The Chemo-Sero Therapeutic Research InstituteInventors: Eiji Tokunaga, Masashi Sakaguchi, Kazuo Matsuo, Fukusaburo Hamada, Sachio Tokiyoshi
-
Patent number: 6913746Abstract: The present invention relates to complexes consisting of immunoglobulins and polysaccharides for oral and transmucosal use. The polysaccharides comprised in the complexes according to the invention form an envelope which protects and carries immunoglobulins allowing their systemic absorption through the gastric and mucosal district. Immunoglobulins have a different specificity depending on the required therapeutic effect. They are used in passive immunoprophylaxis for the prevention or therapy of infections caused by pathogenic agents such as virus, bacteria, parasites, or they are used in the modulation of endogenous bio-chemical balances, or in the detoxification from drugs of abuse, medicines, toxins.Type: GrantFiled: February 20, 2002Date of Patent: July 5, 2005Assignee: Grisotech S.A.Inventors: Rolando Wyss, Bernad Bizzini, Ivo Volpato
-
Patent number: 6884417Abstract: The present invention concerns a method of treating LBP-mediated LPS-induced myeloid cell activation comprising administering a therapeutically effective amount of an anti-LBP monoclonal antibody molecule. A therapeutic composition comprising anti-LBP antibody molecules in a pharmaceutically acceptable excipient is also contemplated.Type: GrantFiled: May 15, 2001Date of Patent: April 26, 2005Assignee: The Scripps Research InstituteInventors: Theo Kirkland, Peter Tobias, Richard Ulevitch, Ann Moriarty, Didier Leturcq
-
Patent number: 6881406Abstract: Methods are provided to specifically modulate the trafficking of systemic memory T cells, particularly CD4+ T cells, without affecting naive T cells or intestinal memory T cells. It is shown that systemic memory T cells, which are characterized as CD45Ra?, and integrin ?4?7?, express high levels of CCR4. Ligands of CCR4, such as TARC or MDC, act as an adhesion trigger, wherein upon CCR4 binding, these cells undergo integrin-dependent arrest to the appropriate vascular receptor(s). This arrest acts to localize the cells at the target site. The methods of the invention manipulate this triggering, and CCR4 mediated chemotaxis, to affect the localization of T cells in targeted tissues. In an alternative embodiment, the agent is an antagonist that blocks CCR4 biological activity. An advantage of the invention is the selectivity for systemic memory T cells, without affecting native T cells or intestinal memory T cells.Type: GrantFiled: April 17, 2001Date of Patent: April 19, 2005Assignees: The Board of Trustees of the Leland Stanford Junior University, Millennium Pharmaceuticals, Inc.Inventors: Eugene C. Butcher, James J. Campbell, Lijun Wu, James B. Rottman
-
Patent number: 6872392Abstract: Chimeric human antibody expression vectors are constructed by inserting the heavy chain variable region-encoding cDNA and antibody light chain variable region-encoding cDNA isolated from hybridomas producing a mouse or rat monoclonal antibody reacting with the ganglioside GM2 respectively into an expression vector which contains the human antibody heavy chain constant region- or human antibody light chain constant region-encoding cDNA. The expression vectors are introduced into animal cells and the transformant thus obtained is cultured to produce a chimeric human antibody reacting with the ganglioside GM2. In contrast to mouse monoclonal antibodies, the chimeric human antibodies of the invention will not cause anti-mouse immunoglobulin antibody production in the patient's body but show a prolonged blood half-life, with a reduced frequency of adverse effects, so that it can be expected to be superior to mouse monoclonal antibodies in the efficacy in the treatment of human cancer, for instance.Type: GrantFiled: July 16, 2002Date of Patent: March 29, 2005Assignee: Kyowa Hakko Kogyo Co., Ltd.Inventors: Kazuyasu Nakamura, Masamichi Koike, Kenya Shitara, Nobuo Hanai, Yoshihisa Kuwana, Mamoru Hasegawa
-
Patent number: 6818213Abstract: Disclosed is the surprising discovery that aminophospholipids, such as phosphatidylserine and phosphatidylethanolamine, are specific, accessible and stable markers of the luminal surface of tumor blood vessels. The present invention thus provides aminophospholipid-targeted diagnostic and therapeutic constructs for use in tumor intervention. Antibody-therapeutic agent conjugates and constructs that bind to aminophospholipids are particularly provided, as are methods of specifically delivering therapeutic agents, including toxins and coagulants, to the stably-expressed aminophospholipids of tumor blood vessels, thereby inducing thrombosis, necrosis and tumor regression.Type: GrantFiled: July 12, 1999Date of Patent: November 16, 2004Assignee: Board of Regents, The University of Texas SystemInventors: Philip E. Thorpe, Sophia Ran, Rolf A. Brekken
-
Patent number: 6815169Abstract: The invention provides isolated nucleic acid and amino acid sequences of TL-&ggr;, antibodies to TL-&ggr;, methods of screening for TL-&ggr; modulators using biologically active TL-&ggr;, and kits for screening for TL-&ggr; modulators.Type: GrantFiled: November 28, 2000Date of Patent: November 9, 2004Assignee: The Regents of the University of CaliforniaInventors: Roman Sakowicz, Lawrence S. B. Goldstein
-
Patent number: 6808710Abstract: The invention identifies PD-1 as a receptor for B7-4. B7-4 can inhibit immune cell activation upon binding to an inhibitory receptor on an immune cell. Accordingly, the invention provides agents for modulating PD-1, B7-4, and the interaction between B7-4 and PD-1 in order to modulate a costimulatory or an inhibitory signal in a immune cell resulting in modulation of the immune response.Type: GrantFiled: August 23, 2000Date of Patent: October 26, 2004Assignees: Genetics Institute, Inc., Dana-Farber Cancer Institute, Inc.Inventors: Clive Wood, Gordon J. Freeman
-
Anti-idiotypic antibody which induces an immune response against a glycosphingolipid and use thereof
Patent number: 6805862Abstract: The present invention provides an anti-idiotypic monoclonal antibody which specifically induces an immune response against a glycosphingolipid. Additionally, this invention provides a method of producing the anti-idiotypic monoclonal antibody. Finally, this invention provides a composition of matter comprising an effective amount of a cytokine and a melanoma ganglio-side-specific antibody attached to a carrier.Type: GrantFiled: June 7, 1995Date of Patent: October 19, 2004Assignee: Sloan-Kattering Institute For Cancer ResearchInventors: Paul B. Chapman, Alan N. Houghton -
Patent number: 6803039Abstract: Immunization of human antibody-producing transgenic mice, which have been created using genetic engineering techniques, with AILIM molecule as an antigen resulted in various human monoclonal antibodies capable of binding to AILIM and capable of controlling a variety of biological reactions (for example, cell proliferation, cytokine production, immune cytolysis, cell death, induction of ADCC, etc.) associated with AILIM-mediated costimulatory signal (secondary signal) transduction. Furthermore, it has been revealed that the human monoclonal antibody is effective to treat and prevent various diseases associated with AILIM-mediated costimulatory signal transduction, being capable of inhibiting the onset and/or advancement of the diseases.Type: GrantFiled: May 16, 2001Date of Patent: October 12, 2004Assignee: Japan Tobacco Inc.Inventors: Takashi Tsuji, Katsunari Tezuka, Nobuaki Hori
-
Patent number: 6790661Abstract: The invention provides methods for screening for the presence of a clinically relevant amount of bacteria in donor blood or a blood product from a donor mammal, particularly blood or a blood product that will be transferred from the donor mammal to a recipient mammal. The method comprises contacting a sample of the donor blood or a blood product with a set of binding agents that comprises binding agents that specifically bind to Gram-negative bacterial antigen and/or binding agents that specifically bind to Gram-positive bacterial antigen, and determining binding of the set of binding agents to the sample, wherein binding indicates the presence of a clinically relevant amount of Gram-positive bacteria and/or Gram-negative bacteria in the donor blood or blood product and no binding indicates the absence of a clinically relevant amount of Gram-positive bacteria and/or Gram-negative bacteria in the donor blood or blood product.Type: GrantFiled: July 14, 2000Date of Patent: September 14, 2004Assignee: Verax Biomedical, Inc.Inventor: Timothy T. Goodnow
-
Patent number: 6783760Abstract: Disclosed is the surprising discovery that aminophospholipids, such as phosphatidylserine and phosphatidylethanolamine, are specific, accessible and stable markers of the luminal surface of tumor blood vessels. The present invention thus provides aminophospholipid-targeted diagnostic and therapeutic constructs for use in tumor intervention. Antibody-therapeutic agent conjugates and constructs that bind to aminophospholipids are particularly provided, as are methods of specifically delivering therapeutic agents, including toxins and coagulants, to the stably-expressed aminophospholipids of tumor blood vessels, thereby inducing thrombosis, necrosis and tumor regression.Type: GrantFiled: March 28, 2001Date of Patent: August 31, 2004Assignee: Board of Regents, The University of Texas SystemInventors: Philip E. Thorpe, Sophia Ran, Rolf A. Brekken
-
Patent number: 6770277Abstract: The gene for Streptococcus pyogenes DNase B has been cloned and vectors incorporating the cloned DNA have been used to transform Escherichia coli, allowing efficient and rapid production of the DNase in E. coli without the necessity of growing large quantities of S. pyogenes. The enzyme can be produced with a leader peptide at its aminoterminus. An improved method for the purification of naturally occurring S. pyogenes DNase B enzyme is also provided. The DNase B enzyme produced, either by purification of naturally occurring enzyme or by recombinant DNA techniques, can be used to generate antibodies and can also be used in immunochemical assays to detect the presence of anti-DNase B antibodies in serum as a marker of infection by S. pyogenes.Type: GrantFiled: June 7, 1995Date of Patent: August 3, 2004Assignee: Beckman Coulter, Inc.Inventors: Craig W Adams, Patty P. Y. Pang, C. Marina Belei
-
Patent number: RE39138Abstract: The present invention relates to monoclonal antibodies to advanced glycosylation endproducts formed in vivo and cross-reactive with advanced glycosylation endproducts formed in vitro, and to methods of diagnosis and therapy based thereon. More particularly, the invention is directed to a monoclonal antibody, or an antigen-binding fragment thereof, reactive with in vivo produced advanced glycosylation endproducts (AGEs), which monoclonal antibody or antigen binding fragment thereof demonstrates an immunological binding characteristic of monoclonal antibody 4G9 as produced by hybridoma 4G9, deposited with the American Type Culture Collection (ATCC) and assigned Accession Number CRL 11626, on Apr. 27, 1994. In a specific embodiment, the 4G9 antibody is used in a sandwich ELISA to detect ApoB-AGE, IgG-AGE, collagen-AGE, serum-AGE peptides and proteins and urinary-AGE peptides and proteins.Type: GrantFiled: December 16, 1999Date of Patent: June 20, 2006Assignee: Alteon IncorporatedInventors: Henry W. Founds, Homayoun Sadeghi